Familial hypocalciuric hypercalcemia differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Familial hypocalciuric hypercalcemia}}
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Familial_hypocalciuric_hypercalcemia]]
{{CMG}}; {{AE}}{{Ajay}}  
{{CMG}}; {{AE}}{{Ajay}}  


Line 55: Line 55:
| colspan="2" style="background: #F0FFFF; text-align: center;" |'''Familial hypocalciuric hypercalcemia'''
| colspan="2" style="background: #F0FFFF; text-align: center;" |'''Familial hypocalciuric hypercalcemia'''
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* This is a genetic disorder caused my mutation in calcium-sensing receptor gene.
* This is a genetic disorder caused by mutation in [[calcium-sensing receptor]] gene.
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* This is a benign condition and does not require treatment.
* This is a benign condition and does not require treatment.
Line 63: Line 63:
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* Calcium/creatinine clearance ratio
* [[Calcium]]/[[creatinine]] clearance ratio
|-
|-
| rowspan="3" style="background: #F0FFFF; text-align: center;" |'''Hyperparathyroidism'''
| rowspan="3" style="background: #F0FFFF; text-align: center;" |'''[[Hyperparathyroidism]]'''
| style="background: #F0FFFF; text-align: center;" |Primary hyperparathyroidism
| style="background: #F0FFFF; text-align: center;" |[[Primary hyperparathyroidism]]
| style="background: #DCDCDC;" |Increase in [[secretion]] of [[parathyroid hormone]] (PTH) from a primary process in the [[parathyroid gland]]. Parathyroid hormone causes an increase in serum calcium.
| style="background: #DCDCDC;" |Increase in [[secretion]] of [[parathyroid hormone]] (PTH) from a primary process in the [[parathyroid gland]]. [[Parathyroid hormone]] causes an increase in serum [[calcium]].
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* Usually asymptomatic
* Usually asymptomatic
* Hypercalcemia detected on routine biochemical  panel
* [[Hypercalcemia]] detected on routine biochemical  panel
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑  
| style="background: #DCDCDC; text-align: center;" |↑  
| style="background: #DCDCDC; text-align: center;" |↓/Normal  
| style="background: #DCDCDC; text-align: center;" |↓/Normal  
| style="background: #DCDCDC; text-align: center;" |Normal/↑ calcitriol
| style="background: #DCDCDC; text-align: center;" |Normal/↑ [[calcitriol]]
| rowspan="3" style="background: #DCDCDC;" |Findings of bone resorption:
| rowspan="3" style="background: #DCDCDC;" |Findings of bone resorption:
* X-ray
* [[X-ray]]
* DXA
* [[DEXA scan|DEXA]]
Preoperative localization of hyperfunctioning parathyroid gland:
Preoperative localization of hyperfunctioning [[parathyroid gland]]:
* Non-Invasive
* Non-Invasive
** Tc-99m sestamibi scintigraphy
** [[Tc-99m sestamibi scintigraphy]]
** Neck ultrasound
** Neck ultrasound
** 4D-CT
** 4D-CT
** SPET(P-SPECT)
** [[SPECT|SPET(P-SPECT)]]
** PET
** [[PET]]
** MRI
** [[MRI]]
* Invasive:
* Invasive:
** Super sensitive venous sampling  
** Super sensitive venous sampling  
** Selective arteriography
** Selective [[arteriography]]
** Angiography
** [[Angiography]]
Predicting post-operative success:
Predicting post-operative success:
* Intraoperative parathyroid hormone monitoring
* Intraoperative [[parathyroid hormone]] monitoring
|-
|-
| style="background: #F0FFFF; text-align: center;" |Secondary hyperparathyroidism
| style="background: #F0FFFF; text-align: center;" |[[Secondary hyperparathyroidism]]
| style="background: #DCDCDC;" |Increase in [[secretion]] of [[parathyroid hormone]] (PTH) from a secondary process. Parathyroid hormone causes an increase in serum calcium.
| style="background: #DCDCDC;" |Increase in [[secretion]] of [[parathyroid hormone]] (PTH) from a secondary process. [[Parathyroid hormone]] causes an increase in serum calcium.
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* May present with history of:
* May present with history of:
** Chronic renal failure
** [[Chronic renal failure]]
** Vitamin D deficiency
** [[Vitamin D deficiency]]
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↓/Normal  
| style="background: #DCDCDC; text-align: center;" |↓/Normal  
Line 105: Line 105:
|-
|-
| style="background: #F0FFFF; text-align: center;" |Tertiary hyperparathyroidism
| style="background: #F0FFFF; text-align: center;" |Tertiary hyperparathyroidism
| style="background: #DCDCDC;" |Continuous elevation of [[parathyroid hormone]] (PTH) even after successful treatment of the secondary cause of elevated parathyroid hormone. Parathyroid hormone causes an increase in serum calcium.
| style="background: #DCDCDC;" |Continuous elevation of [[parathyroid hormone]] (PTH) even after successful treatment of the secondary cause of elevated [[parathyroid hormone]]. [[Parathyroid hormone]] causes an increase in serum [[calcium]].
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* Usually present with a history of:
* Usually present with a history of:
** Kidney transplant
** [[Kidney transplant]]
* Usually hyperplasia of all four parathyroid glands
* Usually [[hyperplasia]] of all four [[parathyroid glands]]
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
Line 117: Line 117:
| rowspan="4" style="background: #F0FFFF; text-align: center;" |'''Malignancy'''<ref name="pmid26713296">{{cite journal |vauthors=Mirrakhimov AE |title=Hypercalcemia of Malignancy: An Update on Pathogenesis and Management |journal=N Am J Med Sci |volume=7 |issue=11 |pages=483–93 |year=2015 |pmid=26713296 |pmc=4683803 |doi=10.4103/1947-2714.170600 |url=}}</ref>
| rowspan="4" style="background: #F0FFFF; text-align: center;" |'''Malignancy'''<ref name="pmid26713296">{{cite journal |vauthors=Mirrakhimov AE |title=Hypercalcemia of Malignancy: An Update on Pathogenesis and Management |journal=N Am J Med Sci |volume=7 |issue=11 |pages=483–93 |year=2015 |pmid=26713296 |pmc=4683803 |doi=10.4103/1947-2714.170600 |url=}}</ref>
| style="background: #F0FFFF; text-align: center;" |Humoral hypercalcemia of malignancy<ref name="pmid1346019">{{cite journal |vauthors=Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG |title=Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia |journal=Lancet |volume=339 |issue=8786 |pages=164–7 |year=1992 |pmid=1346019 |doi=10.1016/0140-6736(92)90220-W |url=}}</ref><ref name="pmid7962324">{{cite journal |vauthors=Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T |title=Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma |journal=J. Clin. Endocrinol. Metab. |volume=79 |issue=5 |pages=1322–7 |year=1994 |pmid=7962324 |doi=10.1210/jcem.79.5.7962324 |url=}}</ref><ref name="pmid12679445">{{cite journal |vauthors=Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF |title=Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=4 |pages=1603–9 |year=2003 |pmid=12679445 |doi=10.1210/jc.2002-020773 |url=}}</ref>
| style="background: #F0FFFF; text-align: center;" |Humoral hypercalcemia of malignancy<ref name="pmid1346019">{{cite journal |vauthors=Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG |title=Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia |journal=Lancet |volume=339 |issue=8786 |pages=164–7 |year=1992 |pmid=1346019 |doi=10.1016/0140-6736(92)90220-W |url=}}</ref><ref name="pmid7962324">{{cite journal |vauthors=Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T |title=Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma |journal=J. Clin. Endocrinol. Metab. |volume=79 |issue=5 |pages=1322–7 |year=1994 |pmid=7962324 |doi=10.1210/jcem.79.5.7962324 |url=}}</ref><ref name="pmid12679445">{{cite journal |vauthors=Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF |title=Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=4 |pages=1603–9 |year=2003 |pmid=12679445 |doi=10.1210/jc.2002-020773 |url=}}</ref>
| style="background: #DCDCDC;" |Tumor cells secrete parathyroidhormone-related protein (PTHrP) which has sima similartion as parathyroid hormone.
| style="background: #DCDCDC;" |Tumor cells secrete [[Parathyroid hormone-related protein|parathyroidhormone-related protein]] ([[PTHrP]]) which acts similarly to [[parathyroid hormone]].
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* Most common cause of malignancy related hypercalcemia.
* Most common cause of [[malignancy]] related [[hypercalcemia]].
* Usually present in solid tumors
* Usually present in solid tumors
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↓/Normal  
| style="background: #DCDCDC; text-align: center;" |↓/Normal  
| style="background: #DCDCDC; text-align: center;" |↑ PTHrP
| style="background: #DCDCDC; text-align: center;" |↑ [[PTHrP]]


Normal/↑ calcitriol
Normal/↑ [[calcitriol]]
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* Chest X-ray
* [[Chest X-ray]]
* CT scan
* [[CT scan]]
* MRI
* [[MRI]]
|-
|-
| style="background: #F0FFFF; text-align: center;" |Osteolytic tumors
| style="background: #F0FFFF; text-align: center;" |Osteolytic tumors
| style="background: #DCDCDC;" |Multiple myelomas produces osteolysis of bones causing hypercalcemia. Osteolytic metastasis can cause bone resorption causing hypercalcemia.
| style="background: #DCDCDC;" |[[Multiple myeloma]] produces [[osteolysis]] of bones causing [[hypercalcemia]]. [[Osteolytic metasteses|Osteolytic metastasis]] can cause bone resorption causing [[hypercalcemia]].
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* Most commonly present in multiple myeloma and breast cancer.
* Most commonly present in [[multiple myeloma]] and [[breast cancer]].
| style="background: #DCDCDC; text-align: center;" |↓
| style="background: #DCDCDC; text-align: center;" |↓
| style="background: #DCDCDC; text-align: center;" |↑  
| style="background: #DCDCDC; text-align: center;" |↑  
Line 141: Line 141:
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* DXA
* [[DXA]]
* X-ray
* [[X-ray]]
* Mammography
* [[Mammography]]
* Ultrasound
* [[Ultrasound]]
* ESR
* [[ESR]]
* Serum protein electrophoresis
* [[Serum protein electrophoresis]]
|-
|-
| style="background: #F0FFFF; text-align: center;" |Production of calcitirol
| style="background: #F0FFFF; text-align: center;" |Production of [[calcitriol]]
| style="background: #DCDCDC;" |Some tumors has ectopic activity of 1-alpha-hydroxylase leading to increased production of calcitriol. Calcitriol is active form of vitamin D and causes hypercalcemia.  
| style="background: #DCDCDC;" |Some tumors have ectopic activity of 1-alpha-hydroxylase leading to increased production of [[calcitriol]]. [[Calcitriol]] is active form of [[vitamin D]] and causes [[hypercalcemia]].  
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* Most commonly present in lymphomas and in some ovarian germ cell tumors.
* Most commonly present in [[lymphomas]] and in some [[Ovarian germ cell tumor|ovarian germ cell tumors]].
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |↑ Calcitriol
| style="background: #DCDCDC; text-align: center;" |↑ [[Calcitriol]]
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* CT scan
* [[CT scan]]
* MRI
* [[MRI]]
|-
|-
| style="background: #F0FFFF; text-align: center;" |Ectopic parathyroid hormone<ref name="pmid16263810">{{cite journal |vauthors=VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R |title=Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene |journal=J. Clin. Endocrinol. Metab. |volume=91 |issue=2 |pages=580–3 |year=2006 |pmid=16263810 |doi=10.1210/jc.2005-2095 |url=}}</ref>
| style="background: #F0FFFF; text-align: center;" |Ectopic [[parathyroid hormone]]<ref name="pmid16263810">{{cite journal |vauthors=VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R |title=Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene |journal=J. Clin. Endocrinol. Metab. |volume=91 |issue=2 |pages=580–3 |year=2006 |pmid=16263810 |doi=10.1210/jc.2005-2095 |url=}}</ref>
| style="background: #DCDCDC;" |Some tumors leads to ectopic production of parathyroid hormone.
| style="background: #DCDCDC;" |Some tumors leads to ectopic production of [[Parathyroid hormone|parathyroid hormone.]]
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* In rare instances, small cell carcinoma of lung may produce hypercalcemia by this process.
* In rare instances, [[small cell carcinoma]] of lung may produce [[hypercalcemia]] by this process.
| style="background: #DCDCDC; text-align: center;" |↑  
| style="background: #DCDCDC; text-align: center;" |↑  
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
Line 169: Line 169:
| style="background: #DCDCDC; text-align: center;" |Normal/↑ Calcitriol
| style="background: #DCDCDC; text-align: center;" |Normal/↑ Calcitriol
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* Chest X-ray
* [[Chest X-ray]]
* CT scan
* [[CT scan]]
* MRI
* [[MRI]]
|-
|-
| rowspan="2" style="background: #F0FFFF; text-align: center;" |'''Medication induced'''
| rowspan="2" style="background: #F0FFFF; text-align: center;" |'''Medication induced'''
| style="background: #F0FFFF; text-align: center;" |Lithium<ref name="pmid2918061">{{cite journal |vauthors=Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S |title=Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume |journal=J. Clin. Endocrinol. Metab. |volume=68 |issue=3 |pages=654–60 |year=1989 |pmid=2918061 |doi=10.1210/jcem-68-3-654 |url=}}</ref>
| style="background: #F0FFFF; text-align: center;" |[[Lithium]]<ref name="pmid2918061">{{cite journal |vauthors=Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S |title=Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume |journal=J. Clin. Endocrinol. Metab. |volume=68 |issue=3 |pages=654–60 |year=1989 |pmid=2918061 |doi=10.1210/jcem-68-3-654 |url=}}</ref>
| style="background: #DCDCDC;" |Lithium lowers urinary calcium and causes hypercalcemia. Lithium has been reported to cause an increase in parathyroid hormones and enlargement if parathyroid gland after weeks to months of therapy.
| style="background: #DCDCDC;" |[[Lithium]] lowers urinary calcium and causes [[hypercalcemia]]. [[Lithium]] has been reported to cause an increase in [[Parathyroid hormone|parathyroid hormones]] and enlargement of [[parathyroid gland]] after weeks to months of therapy.
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* History of mood disorder
* History of mood disorder
Line 183: Line 183:
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* Lithium levels
* [[Lithium]] levels
|-
|-
| style="background: #F0FFFF; text-align: center;" |Thiazide diuretics
| style="background: #F0FFFF; text-align: center;" |[[Thiazide diuretics]]
| style="background: #DCDCDC;" |Thiazide diuretics lowers urinary calcium excretion and causes hypercalcemia
| style="background: #DCDCDC;" |[[Thiazide diuretics]] lowers urinary calcium excretion and causes [[hypercalcemia]]
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* History of cardiac disorder
* History of cardiac disorder
* Rarely causes hypercalcemia
* Rarely causes [[hypercalcemia]]
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
Line 197: Line 197:
|-
|-
| rowspan="2" style="background: #F0FFFF; text-align: center;" |'''Nutritional'''
| rowspan="2" style="background: #F0FFFF; text-align: center;" |'''Nutritional'''
| style="background: #F0FFFF; text-align: center;" |Milk-alkali syndrome
| style="background: #F0FFFF; text-align: center;" |[[Milk-alkali syndrome]]
| style="background: #DCDCDC;" |Hypercalcemia is be caused by high intake of calcium carbonate
| style="background: #DCDCDC;" |[[Hypercalcemia]] caused by high intake of [[calcium carbonate]]
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* History of
* History of
** High milk intake
** High milk intake
** Excess calcium intake for treating:
** Excess calcium intake for treating:
*** Osteoporosis
*** [[Osteoporosis]]
*** Dyspepsia
*** [[Dyspepsia]]
* May lead to metabolic alkalosis and renal insufficiency.
* May lead to [[metabolic alkalosis]] and renal insufficiency.
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
Line 211: Line 211:
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* Renal function test
* [[Renal function tests|Renal function test]]
|-
|-
| style="background: #F0FFFF; text-align: center;" |Vitamin D toxicity
| style="background: #F0FFFF; text-align: center;" |[[Vitamin D Intoxication|Vitamin D toxicity]]
| style="background: #DCDCDC;" |Excess vitamin D causes increased absorption of calcium from intestine causing hypercalcemia.
| style="background: #DCDCDC;" |Excess [[vitamin D]] causes increased absorption of [[calcium]] from intestine causing [[hypercalcemia]].
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* History of:
* History of:
** Excess intake vitamin D
** Excess intake [[vitamin D]]
** Excess milk fortified with vitamin D<ref name="pmid1313547">{{cite journal |vauthors=Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW |title=Hypervitaminosis D associated with drinking milk |journal=N. Engl. J. Med. |volume=326 |issue=18 |pages=1173–7 |year=1992 |pmid=1313547 |doi=10.1056/NEJM199204303261801 |url=}}</ref>
** Excess milk fortified with [[vitamin D]]<ref name="pmid1313547">{{cite journal |vauthors=Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW |title=Hypervitaminosis D associated with drinking milk |journal=N. Engl. J. Med. |volume=326 |issue=18 |pages=1173–7 |year=1992 |pmid=1313547 |doi=10.1056/NEJM199204303261801 |url=}}</ref>
** Topical application of vitamin D analogue analogue calcipotriol<ref name="pmid8120527">{{cite journal |vauthors=Hoeck HC, Laurberg G, Laurberg P |title=Hypercalcaemic crisis after excessive topical use of a vitamin D derivative |journal=J. Intern. Med. |volume=235 |issue=3 |pages=281–2 |year=1994 |pmid=8120527 |doi= |url=}}</ref>
** Topical application of [[vitamin D]] analogue [[calcipotriol]]<ref name="pmid8120527">{{cite journal |vauthors=Hoeck HC, Laurberg G, Laurberg P |title=Hypercalcaemic crisis after excessive topical use of a vitamin D derivative |journal=J. Intern. Med. |volume=235 |issue=3 |pages=281–2 |year=1994 |pmid=8120527 |doi= |url=}}</ref>
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |↑ Vitamin D (calcidiol and/or calcitriol)
| style="background: #DCDCDC; text-align: center;" |↑ [[Vitamin D]] ([[calcidiol]] and/or [[calcitriol]])
| style="background: #DCDCDC;" | --
| style="background: #DCDCDC;" | --
|-
|-
| style="background: #F0FFFF; text-align: center;" |'''Granulomatous disease'''
| style="background: #F0FFFF; text-align: center;" |'''[[Granulomatous|Granulomatous disease]]'''
| style="background: #F0FFFF; text-align: center;" |Sarcoidosis<ref name="pmid9215298">{{cite journal |vauthors=Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E |title=gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=7 |pages=2222–32 |year=1997 |pmid=9215298 |doi=10.1210/jcem.82.7.4074 |url=}}</ref>
| style="background: #F0FFFF; text-align: center;" |[[Sarcoidosis]]<ref name="pmid9215298">{{cite journal |vauthors=Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E |title=gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=7 |pages=2222–32 |year=1997 |pmid=9215298 |doi=10.1210/jcem.82.7.4074 |url=}}</ref>
| style="background: #DCDCDC;" |Hypercalcemia is causes by endogeous production of calcitriol by disease-activated macrophages.
| style="background: #DCDCDC;" |[[Hypercalcemia]] is caused by endogenous production of [[calcitriol]] by disease-activated [[macrophages]].
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* History of:
* History of:
** Cough
** [[Cough]]
** Dyspnea
** [[Dyspnea]]
** Chest pain
** [[Chest pain]]
** Tiredness or weakness
** Tiredness or weakness
** Fever
** [[Fever]]
** Weight loss
** [[Weight loss]]
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" |↑
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" | --
| style="background: #DCDCDC; text-align: center;" |
| style="background: #DCDCDC; text-align: center;" |
* ↑ Calcitriol
* ↑ [[Calcitriol]]
* ↑ ACE levels
* ↑ [[ACE|ACE levels]]
| style="background: #DCDCDC;" |
| style="background: #DCDCDC;" |
* Chest X-ray
* [[Chest X-ray]]
* Biopsy
* [[Biopsy]]
|}
|}



Latest revision as of 20:40, 26 February 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ajay Gade MD[2]]

Overview

Familial hypocalciuric hypercalcemia must be differentiated from primary hyperparathyroidism to avoid unnecessary parathyroidectomy. Calcium creatinine clearance ratio is used to differentiate FHH from primary hyperparathyroidism, ratio < 0.01 suggestive of FHH and > 0.01 suggestive of primary hyperparathyroidism. This genetic test of the CaSR gene is the gold standard. If negative, genetic testing for mutation of G alpha 11 and AP2S1 can diagnose FHH2 and FHH3, respectively.

Differentiating Familial Hypocalciuric Hypercalcemia From Other Diseases

Familial hypocalciuric hypercalcemia should be differentiated from other causes of hypercalcemia. Causes of hypercalcemia include:

Parathyroid-related Non-parathyroid related Medication-induced Other
Differential diagnosis of Familial Hypocalciuric Hypercalcemia on the basis of hypercalcemia
Disorder Mechanism of hypercalcemia Clinical features Laboratory findings Imaging & diagnostic modalities
PTH Calcium Phosphate Other findings
Familial hypocalciuric hypercalcemia
  • This is a benign condition and does not require treatment.
Normal/↑ Normal/↑ --
Hyperparathyroidism Primary hyperparathyroidism Increase in secretion of parathyroid hormone (PTH) from a primary process in the parathyroid gland. Parathyroid hormone causes an increase in serum calcium.
  • Usually asymptomatic
  • Hypercalcemia detected on routine biochemical panel
↓/Normal Normal/↑ calcitriol Findings of bone resorption:

Preoperative localization of hyperfunctioning parathyroid gland:

Predicting post-operative success:

Secondary hyperparathyroidism Increase in secretion of parathyroid hormone (PTH) from a secondary process. Parathyroid hormone causes an increase in serum calcium. ↓/Normal --
Tertiary hyperparathyroidism Continuous elevation of parathyroid hormone (PTH) even after successful treatment of the secondary cause of elevated parathyroid hormone. Parathyroid hormone causes an increase in serum calcium. --
Malignancy[1] Humoral hypercalcemia of malignancy[2][3][4] Tumor cells secrete parathyroidhormone-related protein (PTHrP) which acts similarly to parathyroid hormone. -- ↓/Normal PTHrP

Normal/↑ calcitriol

Osteolytic tumors Multiple myeloma produces osteolysis of bones causing hypercalcemia. Osteolytic metastasis can cause bone resorption causing hypercalcemia. -- --
Production of calcitriol Some tumors have ectopic activity of 1-alpha-hydroxylase leading to increased production of calcitriol. Calcitriol is active form of vitamin D and causes hypercalcemia. -- -- Calcitriol
Ectopic parathyroid hormone[5] Some tumors leads to ectopic production of parathyroid hormone. ↓/Normal Normal/↑ Calcitriol
Medication induced Lithium[6] Lithium lowers urinary calcium and causes hypercalcemia. Lithium has been reported to cause an increase in parathyroid hormones and enlargement of parathyroid gland after weeks to months of therapy.
  • History of mood disorder
-- --
Thiazide diuretics Thiazide diuretics lowers urinary calcium excretion and causes hypercalcemia -- -- -- --
Nutritional Milk-alkali syndrome Hypercalcemia caused by high intake of calcium carbonate -- -- --
Vitamin D toxicity Excess vitamin D causes increased absorption of calcium from intestine causing hypercalcemia. -- -- Vitamin D (calcidiol and/or calcitriol) --
Granulomatous disease Sarcoidosis[9] Hypercalcemia is caused by endogenous production of calcitriol by disease-activated macrophages. -- --

References

  1. Mirrakhimov AE (2015). "Hypercalcemia of Malignancy: An Update on Pathogenesis and Management". N Am J Med Sci. 7 (11): 483–93. doi:10.4103/1947-2714.170600. PMC 4683803. PMID 26713296.
  2. Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG (1992). "Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia". Lancet. 339 (8786): 164–7. doi:10.1016/0140-6736(92)90220-W. PMID 1346019.
  3. Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T (1994). "Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma". J. Clin. Endocrinol. Metab. 79 (5): 1322–7. doi:10.1210/jcem.79.5.7962324. PMID 7962324.
  4. Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF (2003). "Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers". J. Clin. Endocrinol. Metab. 88 (4): 1603–9. doi:10.1210/jc.2002-020773. PMID 12679445.
  5. VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R (2006). "Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene". J. Clin. Endocrinol. Metab. 91 (2): 580–3. doi:10.1210/jc.2005-2095. PMID 16263810.
  6. Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S (1989). "Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume". J. Clin. Endocrinol. Metab. 68 (3): 654–60. doi:10.1210/jcem-68-3-654. PMID 2918061.
  7. Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW (1992). "Hypervitaminosis D associated with drinking milk". N. Engl. J. Med. 326 (18): 1173–7. doi:10.1056/NEJM199204303261801. PMID 1313547.
  8. Hoeck HC, Laurberg G, Laurberg P (1994). "Hypercalcaemic crisis after excessive topical use of a vitamin D derivative". J. Intern. Med. 235 (3): 281–2. PMID 8120527.
  9. Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E (1997). "gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses". J. Clin. Endocrinol. Metab. 82 (7): 2222–32. doi:10.1210/jcem.82.7.4074. PMID 9215298.

Template:WH Template:WS